BOLT BIOTHERAPEUTICS INC (BOLT) Fundamental Analysis & Valuation

NASDAQ:BOLT • US0977022039

Current stock price

4.7 USD
+0.1 (+2.17%)
Last:

This BOLT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. BOLT Profitability Analysis

1.1 Basic Checks

  • BOLT had negative earnings in the past year.
  • BOLT had a negative operating cash flow in the past year.
  • BOLT had negative earnings in each of the past 5 years.
  • In the past 5 years BOLT always reported negative operating cash flow.
BOLT Yearly Net Income VS EBIT VS OCF VS FCFBOLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M

1.2 Ratios

  • The Return On Assets of BOLT (-58.81%) is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -125.92%, BOLT is doing worse than 60.73% of the companies in the same industry.
Industry RankSector Rank
ROA -58.81%
ROE -125.92%
ROIC N/A
ROA(3y)-55.16%
ROA(5y)-47.24%
ROE(3y)-99.22%
ROE(5y)-77.69%
ROIC(3y)N/A
ROIC(5y)N/A
BOLT Yearly ROA, ROE, ROICBOLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -5K -10K -15K -20K

1.3 Margins

  • BOLT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BOLT Yearly Profit, Operating, Gross MarginsBOLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. BOLT Health Analysis

2.1 Basic Checks

  • BOLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BOLT has about the same amout of shares outstanding than it did 1 year ago.
  • BOLT has more shares outstanding than it did 5 years ago.
  • BOLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BOLT Yearly Shares OutstandingBOLT Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M
BOLT Yearly Total Debt VS Total AssetsBOLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -12.61, we must say that BOLT is in the distress zone and has some risk of bankruptcy.
  • BOLT's Altman-Z score of -12.61 is on the low side compared to the rest of the industry. BOLT is outperformed by 77.76% of its industry peers.
  • There is no outstanding debt for BOLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.61
ROIC/WACCN/A
WACC9.21%
BOLT Yearly LT Debt VS Equity VS FCFBOLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M

2.3 Liquidity

  • BOLT has a Current Ratio of 3.59. This indicates that BOLT is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.59, BOLT is in line with its industry, outperforming 43.71% of the companies in the same industry.
  • BOLT has a Quick Ratio of 3.59. This indicates that BOLT is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of BOLT (3.59) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.59
Quick Ratio 3.59
BOLT Yearly Current Assets VS Current LiabilitesBOLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. BOLT Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 41.38% over the past year.
  • The Revenue has been growing slightly by 0.07% in the past year.
  • The Revenue has been growing by 101.79% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)41.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.47%
Revenue 1Y (TTM)0.07%
Revenue growth 3Y10.33%
Revenue growth 5Y101.79%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -2.10% on average over the next years.
  • Based on estimates for the next years, BOLT will show a very strong growth in Revenue. The Revenue will grow by 37.26% on average per year.
EPS Next Y-11.5%
EPS Next 2Y-8.11%
EPS Next 3Y-7.67%
EPS Next 5Y-2.1%
Revenue Next Year-41.54%
Revenue Next 2Y16.8%
Revenue Next 3Y15.95%
Revenue Next 5Y37.26%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BOLT Yearly Revenue VS EstimatesBOLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5M 10M 15M 20M 25M
BOLT Yearly EPS VS EstimatesBOLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

0

4. BOLT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BOLT. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BOLT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BOLT Price Earnings VS Forward Price EarningsBOLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BOLT Per share dataBOLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20

4.3 Compensation for Growth

  • A cheap valuation may be justified as BOLT's earnings are expected to decrease with -7.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.11%
EPS Next 3Y-7.67%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BOLT Dividend Analysis

5.1 Amount

  • BOLT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BOLT Fundamentals: All Metrics, Ratios and Statistics

BOLT BIOTHERAPEUTICS INC

NASDAQ:BOLT (4/9/2026, 2:22:19 PM)

4.7

+0.1 (+2.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-11
Inst Owners25.29%
Inst Owner Change0%
Ins Owners5.49%
Ins Owner Change1.41%
Market Cap9.02M
Revenue(TTM)7.70M
Net Income(TTM)-33.38M
Analysts78
Price Target29.58 (529.36%)
Short Float %0.05%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.67%
Min EPS beat(2)36.99%
Max EPS beat(2)38.35%
EPS beat(4)4
Avg EPS beat(4)32.28%
Min EPS beat(4)21.57%
Max EPS beat(4)38.35%
EPS beat(8)7
Avg EPS beat(8)21.51%
EPS beat(12)11
Avg EPS beat(12)17.43%
EPS beat(16)14
Avg EPS beat(16)15.35%
Revenue beat(2)2
Avg Revenue beat(2)230.48%
Min Revenue beat(2)193.31%
Max Revenue beat(2)267.65%
Revenue beat(4)4
Avg Revenue beat(4)158.2%
Min Revenue beat(4)56.1%
Max Revenue beat(4)267.65%
Revenue beat(8)6
Avg Revenue beat(8)89.02%
Revenue beat(12)9
Avg Revenue beat(12)65.53%
Revenue beat(16)13
Avg Revenue beat(16)80.26%
PT rev (1m)8.41%
PT rev (3m)8.41%
EPS NQ rev (1m)32.22%
EPS NQ rev (3m)32.22%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)57.89%
Revenue NQ rev (3m)57.89%
Revenue NY rev (1m)28.57%
Revenue NY rev (3m)28.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.17
P/FCF N/A
P/OCF N/A
P/B 0.34
P/tB 0.34
EV/EBITDA N/A
EPS(TTM)-17.82
EYN/A
EPS(NY)-19.87
Fwd EYN/A
FCF(TTM)-20.79
FCFYN/A
OCF(TTM)-20.76
OCFYN/A
SpS4.01
BVpS13.8
TBVpS13.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -58.81%
ROE -125.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.16%
ROA(5y)-47.24%
ROE(3y)-99.22%
ROE(5y)-77.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.58%
Cap/Sales 0.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.59
Quick Ratio 3.59
Altman-Z -12.61
F-Score5
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)6.33%
Cap/Depr(5y)66.48%
Cap/Sales(3y)1.36%
Cap/Sales(5y)44.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.47%
EPS Next Y-11.5%
EPS Next 2Y-8.11%
EPS Next 3Y-7.67%
EPS Next 5Y-2.1%
Revenue 1Y (TTM)0.07%
Revenue growth 3Y10.33%
Revenue growth 5Y101.79%
Sales Q2Q%N/A
Revenue Next Year-41.54%
Revenue Next 2Y16.8%
Revenue Next 3Y15.95%
Revenue Next 5Y37.26%
EBIT growth 1Y49.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-260.33%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.98%
OCF growth 3YN/A
OCF growth 5YN/A

BOLT BIOTHERAPEUTICS INC / BOLT Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BOLT BIOTHERAPEUTICS INC (BOLT) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BOLT.


Can you provide the valuation status for BOLT BIOTHERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to BOLT BIOTHERAPEUTICS INC (BOLT). This can be considered as Overvalued.


How profitable is BOLT BIOTHERAPEUTICS INC (BOLT) stock?

BOLT BIOTHERAPEUTICS INC (BOLT) has a profitability rating of 0 / 10.


Can you provide the financial health for BOLT stock?

The financial health rating of BOLT BIOTHERAPEUTICS INC (BOLT) is 6 / 10.